BiotechTube
Home/H.U. Group Holdings/Tatsuya Maruyama
TM

Tatsuya Maruyama

Senior Managing Executive Officer, Group CFO

H.U. Group Holdings

Therapeutic Areas

OncologyNeurologyInfectious DiseaseGeneral Healthcare

H.U. Group Holdings Pipeline

DrugIndicationPhase
Lumipulse G β-Amyloid Ratio (1-42/1-40)Alzheimer's Disease DiagnosisApproved
Lumipulse G pTau181Alzheimer's Disease DiagnosisLaunched
HISCL™ Assay PortfolioVarious (Infectious Disease, Tumor Markers)Commercial
Tumor Marker Portfolio (PSA, CA125, etc.)Various CancersCommercial
Companion Diagnostics (CDx) PartnershipsOncology (Various Targets)Development & Commercial

Leadership Team at H.U. Group Holdings

SM
Shuji Morita
President and Representative Director, Group CEO
HO
Hiroshi Oshima
Senior Managing Executive Officer, President of SRL, Inc.
HN
Hironobu Nakamura
Managing Executive Officer, President of Fujirebio Inc.
YW
Yoko Wake
Independent Outside Director (Attorney-at-law)
TI
Tetsuya Iizuka
Independent Outside Director (Professor)
MG
Masahiko Gemma
Independent Outside Director (Corporate Auditor)
View full H.U. Group Holdings profile